Others have shown that Notch and Akt-specific inhibitors can reverse resistance to erlotinib in TKI-resistant lung cancer cells and that Notch/Akt driven resistance is associated with upregulation of the oncogenic miR-233 [157]. The gene discussed is AKT1; the disease is lung carcinoma.